INDV insider transaction filings
Indivior Pharmaceuticals, Inc. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-27. Screen INDV transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings by 1 insider — 3,000 shares, $107,955 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 18,586 shares, $764,628 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 18,586 shares @ $41.14 ($764,628) by Heidbreder Christian, filed 2026-07-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Heidbreder Christian — Chief Scientific Officer | 1 | — | 1 leg · 18,586 sh · $764,628 | — |
| Anderson Woodrow D — Chief Accounting Officer | 2 | 2 legs · 3,000 sh · $107,955 | — | — |
Recent Form 4 filings — Indivior Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-27 | 4 | Anderson Woodrow D — Chief Accounting Officer | Purchase (P): 1,500 @ $35.69 | EDGAR |
| 2026-08-05 | 4 | Anderson Woodrow D — Chief Accounting Officer | Purchase (P): 1,500 @ $36.28 | EDGAR |
| 2026-07-13 | 4 | Heidbreder Christian — Chief Scientific Officer | Sale (S): 18,586 @ $41.14 | EDGAR |
| 2026-06-23 | 4 | Ciaffoni Joseph — Chief Executive Officer, Director | Option exercise (M): 1,266,903 · Tax withholding (F): 612,549 @ $38.32 · Option exercise (M): 1,266,903 (derivative) | EDGAR |
| 2026-06-12 | 4 | Heidbreder Christian — Chief Scientific Officer | Sale (S): 18,586 @ $38.06 | EDGAR |
| 2026-06-10 | 4 | Preblick Ryan — Chief Financial Officer | Sale (S): 36,000 @ $37.70 | EDGAR |
| 2026-05-14 | 4 | Humphreys Keith — Director | Grant/award (A): 6,518 @ $0 | EDGAR |
| 2026-05-14 | 4 | Ryan Barbara — Director | Grant/award (A): 6,518 @ $0 | EDGAR |
| 2026-05-14 | 4 | Wheadon David E. — Director | Grant/award (A): 10,430 @ $0 | EDGAR |
| 2026-05-14 | 4 | Thompson Juliet — Director | Tax withholding (F): 1,117 @ $38.28 · Grant/award (A): 6,518 @ $0 | EDGAR |
| 2026-05-14 | 4 | Stejbach Mark — Director | Grant/award (A): 6,518 @ $0 | EDGAR |
| 2026-05-14 | 4 | Kingsley Stuart A — Director | Grant/award (A): 6,518 @ $0 | EDGAR |
| 2026-05-14 | 4 | NINIVAGGI DANIEL A — Director | Grant/award (A): 6,518 @ $0 | EDGAR |
| 2026-03-17 | 4 | Preblick Ryan — Chief Financial Officer | Option exercise (M): 6,302 · Tax withholding (F): 2,843 @ $31.11 · Option exercise (M): 6,302 (derivative) | EDGAR |
| 2026-03-13 | 4 | Ryan Barbara — Director | Purchase (P): 8 @ $31.09 | EDGAR |
| 2026-03-11 | 4 | Ryan Barbara — Director | Purchase (P): 31 @ $32.56 | EDGAR |
| 2026-03-11 | 4 | Kingsley Stuart A — Director | Purchase (P): 940 @ $31.86 | EDGAR |
| 2026-03-05 | 4 | Preblick Ryan — Chief Financial Officer | Tax withholding (F): 87,597 @ $31.98 · Option exercise (M): 86,949 · Option exercise (M): 113,510 (derivative) | EDGAR |
| 2026-03-05 | 4 | Heidbreder Christian — Chief Scientific Officer | Option exercise (M): 101,544 · Tax withholding (F): 45,797 @ $31.98 · Option exercise (M): 132,565 (derivative) | EDGAR |
| 2026-03-05 | 4 | Anderson Woodrow D — Chief Accounting Officer | Option exercise (M): 18,364 · Tax withholding (F): 8,283 @ $31.98 · Option exercise (M): 5,946 · Tax withholding (F): 2,682 @ $31.98 · Option exercise (M): 23,975 (derivative) · Option exercise (M): 5,946 (derivative) | EDGAR |
| 2026-03-05 | 4 | Burris Jeffrey W — Chief Legal Officer | Option exercise (M): 79,893 · Tax withholding (F): 36,032 @ $31.98 · Option exercise (M): 104,300 (derivative) | EDGAR |
| 2026-02-12 | 4 | Preblick Ryan — Chief Financial Officer | Grant/award (A): 37,358 @ $0 · Grant/award (A): 113,510 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Heidbreder Christian — Chief Scientific Officer | Grant/award (A): 33,622 @ $0 · Grant/award (A): 132,565 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Anderson Woodrow D — Chief Accounting Officer | Grant/award (A): 6,903 @ $0 · Grant/award (A): 23,975 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Barry Patrick A — Chief Commercial Officer | Grant/award (A): 31,380 @ $0 | EDGAR |
| 2026-02-12 | 4 | Burris Jeffrey W — Chief Legal Officer | Grant/award (A): 26,897 @ $0 · Grant/award (A): 104,300 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Ciaffoni Joseph — Chief Executive Officer, Director | Grant/award (A): 79,976 @ $0 | EDGAR |
| 2026-01-28 | 4 | Humphreys Keith — Director | Grant/award (A): 3,722 @ $0 | EDGAR |
| 2026-01-28 | 4 | Ryan Barbara — Director | Grant/award (A): 3,722 @ $0 | EDGAR |
| 2026-01-28 | 4 | Wheadon David E. — Director | Grant/award (A): 5,955 @ $0 | EDGAR |
| 2026-01-28 | 4 | Thompson Juliet — Director | Grant/award (A): 3,722 @ $0 | EDGAR |
| 2026-01-28 | 4 | Stejbach Mark — Director | Grant/award (A): 3,722 @ $0 | EDGAR |
| 2026-01-28 | 4 | Kingsley Stuart A — Director | Grant/award (A): 3,722 @ $0 | EDGAR |
| 2026-01-28 | 4 | NINIVAGGI DANIEL A — Director | Grant/award (A): 3,722 @ $0 | EDGAR |
| 2026-01-07 | 4 | Humphreys Keith — Director | Purchase (P): 775 @ $35.39 | EDGAR |
| 2026-01-07 | 4 | Ryan Barbara — Director | Purchase (P): 775 @ $35.39 | EDGAR |
| 2026-01-07 | 4 | Wheadon David E. — Director | Purchase (P): 1,771 @ $35.39 | EDGAR |
| 2026-01-07 | 4 | Stejbach Mark — Director | Purchase (P): 775 @ $35.39 | EDGAR |
| 2026-01-07 | 4 | NINIVAGGI DANIEL A — Director | Purchase (P): 775 @ $35.39 | EDGAR |
Recent 8-K events — Indivior Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INDV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →